Related Experiment Videos
The Role of 18F-FDG-PET/CT in Pediatric Sarcoma
Douglas J Harrison1, Marguerite T Parisi2, Barry L Shulkin3
1Division of Pediatrics, MD Anderson Cancer Center, Houston, TX.
Insights
18F-FDG-PET/CT shows promise for staging pediatric sarcomas, especially for skeletal metastases. However, its role in predicting outcomes for Ewing sarcoma and rhabdomyosarcoma requires further investigation.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiology
Background:
- 18F-FDG-PET/CT is increasingly used in pediatric oncology.
- Its precise role in managing pediatric sarcomas is under debate.
- Current literature presents conflicting evidence on its prognostic value.
Purpose of the Study:
- To evaluate the current role of 18F-FDG-PET/CT in staging and prognostication of pediatric sarcomas.
- To identify areas of consensus and controversy regarding its clinical application.
- To highlight the need for further research in specific pediatric sarcoma subtypes.
Main Methods:
- Systematic review of existing literature on 18F-FDG-PET/CT in pediatric sarcomas.
- Analysis of studies focusing on osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma.
- Comparison of 18F-FDG-PET/CT performance against other imaging modalities like bone scintigraphy.
Main Results:
- 18F-FDG-PET/CT demonstrates high sensitivity and specificity for detecting skeletal metastases in osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma.
- Its utility in identifying pulmonary metastases is less established.
- Changes in maximal standardized uptake value (SUVmax) may predict treatment response and outcomes in osteosarcoma, but findings are conflicting for other subtypes.
Conclusions:
- 18F-FDG-PET/CT is valuable for staging pediatric sarcomas, particularly for skeletal metastases.
- Its prognostic role is unclear for Ewing sarcoma and rhabdomyosarcoma, necessitating further research.
- Prospective, larger studies are required to define optimal integration of 18F-FDG-PET/CT into pediatric sarcoma treatment protocols.
Abstract:
Considerable debate remains regarding how best to incorporate 18F-FDG-PET/CT into clinical practice for pediatric sarcomas. Although there is a clear role for 18F-FDG-PET/CT in staging pediatric sarcoma, the value of 18F-FDG-PET/CT in prognostication for pediatric sarcomas remains unclear. In osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma, 18F-FDG-PET/CT may be most useful in the identification of skeletal metastases, where the literature consistently suggests that it has improved sensitivity and specificity as compared to bone scintigraphy. The role of the imaging modality in the identification of pulmonary metastatic disease is less clear. Further controversy exists regarding the use of 18F-FDG-PET/CT in predicting outcome. Several studies, particularly in osteosarcoma, suggest changes in the maximal standardized uptake value (SUVmax) that can predict histologic response following neoadjuvant chemotherapy as well as overall outcome. Conversely, studies are conflicting regarding the use of 18F-FDG-PET/CT as a prognostic tool in Ewing sarcoma and rhabdomyosarcoma. The role of 18F-FDG-PET/CT in pediatric nonrhabdomyosarcoma soft tissue sarcomas is unknown at this time. Although most studies have been small and retrospective, in certain histologic subtypes, there is a clear role for the use of this imaging modality. Additional prospective and larger studies are needed to fully determine how best to incorporate 18F-FDG-PET/CT into treatment regimens for pediatric sarcomas in the future.